Novartis headquarters

Novartis | Tropifexor and licogliflozin

Novartis has two NASH prospects in phase 2. The first, tropifexor, is one of a crowd of FXR agonists, and the second, licogliflozin, is an SGLT1/2 inhibitor, which works by blocking the absorption and reabsorption of glucose—a mechanism familiar to diabetes that could make a dent in NASH.